Efficacy of posaconazole in murine experimental sporotrichosis.

Abstract

We developed a murine model of systemic sporotrichosis by using three strains of each of the two commonest species causing sporotrichosis, i.e., Sporothrix schenckii sensu stricto and Sporothrix brasiliensis, in order to evaluate the efficacy of posaconazole (PSC). The drug was administered at a dose of 2.5 or 5 mg/kg of body weight twice a day by gavage, and one group was treated with amphotericin B (AMB) as a control treatment. Posaconazole, especially at 5 mg/kg, showed good efficacy against all the strains tested, regardless of their MICs, as measured by prolonged survival, tissue burden reduction, and histopathology.

• Authors: Fabiola Fernández-Silva, Javier Capilla, Emilio Mayayo, Josep Guarro
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 56 Issue 5 Pg. 2273-7 (May 2012) ISSN: 1098-6596 [Electronic] United States
• PMID: 22330929 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Triazoles
• posaconazole
• Amphotericin B

Topics

• Administration, Oral
• Amphotericin B (administration & dosage, therapeutic use)
• Animals
• Antifungal Agents (administration & dosage, therapeutic use)
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Histocytochemistry
• Liver (drug effects, microbiology)
• Male
• Mice
• Microbial Sensitivity Tests
• Species Specificity
• Sporothrix (drug effects, physiology)
• Sporotrichosis (drug therapy, microbiology, mortality, pathology)
• Survival Rate
• Treatment Outcome
• Triazoles (administration & dosage, therapeutic use)